When was Maculaser founded?

Maculaser was founded in 2018 and raised its 1st funding round 3 years after it was founded.

Where is Maculaser located?

Maculaser is headquartered in Espoo, Finland.

Who is the current CEO of Maculaser?

Jani Tirronen of Maculaser. They have also founded 1 company.

How many employees does Maculaser have?

As of Jul 01, 2024, the latest employee count at Maculaser is 5.

Is Maculaser a funded company?

Maculaser is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on Feb 10, 2021.

When was the latest funding round of Maculaser?

Maculaser's latest funding was a $***** Seed round on Feb 10, 2021, with participation from 2 investors.

Where does Maculaser rank among its competitors?

Maculaser ranks 21st amongst 43 active competitors, of which 13 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Second Sight, which secured $1.1M in Jul, 2022.

Who are the top competitors of Maculaser?

Maculaser's top competitors include Neurotech, Pykus Therapeutics and Eyedaptic. Among them, Second Sight secured the most recent funding round in July, 2022.

Maculaser - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of laser therapy for the treatment of retinal diseases. It has developed treatment solutions for common retinal diseases including dry age-related macular degeneration. It helps in temperature control of the macula during non-damaging laser treatments. The treatment solutions mechanisms treat the root causes of AMD that reduce oxidative stress, prevent the aggregation of proteins, improve the transport of nutrients, and enhance RPEs cytoprotective mechanisms.

Website: maculaser.com
Social

Key Metrics

Founded Year

2018

Location

Espoo, Finland

Stage

Seed

Total Funding

$1.45M in 1 round

Latest Funding Round

Seed, Feb 10, 2021, $*****

Investors

Innovestor & 2 more

Ranked

21^st among 43 active competitors

Employee Count

5 as on Jul 01, 2024

Similar Companies

Neurotech & 49 more

View Maculaser's full profile

Maculaser has raised a total funding of $1.45M over 1 round. Its latest funding round was a Seed round on Feb 10, 2021 for $*****. 2 investors participated in its latest round. Maculaser has 2 institutional investors and 1 angel investor.

Here is the list of recent funding rounds of Maculaser:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 10, 2021	5109163	Seed	7711976	2439310	3042925	7085757

Access funding benchmarks and valuations. Sign up today!

View details of Maculaser's funding rounds and investors

The founders of Maculaser are Ossi Kaikkonen, Jani Tirronen and Teemu Turunen. Jani Tirronen is the CEO of Maculaser.

Here are the details of Maculaser's key team members:

Ossi Kaikkonen: Co-Founder of Maculaser.
Contact Info: 1 email address
Jani Tirronen: Co-Founder & CEO of Maculaser.
Contact Info: 1 email address
Teemu Turunen: Co-Founder of Maculaser.
Contact Info: 1 email address

View details of Maculaser's Founder profiles and Board Members

Maculaser's employee count trend

Maculaser has 5 employees as of Jul 24. Here is Maculaser's employee count trend over the years:

Uncover Maculaser's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Maculaser include Neurotech, Pykus Therapeutics and Eyedaptic. Here is the list of Top 10 competitors of Maculaser, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Neurotech 2000, Cumberland (United States), Series B	Developer of a cell-based delivery device for the treatment of eye diseases	$53.3M	Apax, Atlas Venture & 12 others	56/100
2nd	Pykus Therapeutics 2016, Boston (United States), Seed	Develops a dissolvable intraocular device for use during retinal surgery	$2.49M	Astellas Venture Management, Hongsen Investment ... & 5 others	50/100
3rd	Eyedaptic 2016, Laguna Niguel (United States), Seed	Smart glasses enhancing vision for macular degeneration and low vision	$1.47M	New York Angels, Crescite Ventures & 2 others	48/100
4th	Pixium Vision 2011, Paris (France), Public	Provider of bionic vision restoration systems	$32.5M	Sofinnova Partners, Lifeblood Capital & 11 others	48/100
5th	Second Sight 2000, Los Angeles (United States), Public	Provider of an implantable visual prosthetic for blind individuals	$36.9M	Versant Ventures, MDB Capital & 2 others	47/100
6th	RecensMedical 2016, Ulsan (South Korea), Public	Developer of an anesthetic medical device for retinal diseases	-	Tech Incubator Program for Startup, Intops Investment ... & 3 others	45/100
7th	iScience Interventional 1999, Menlo Park (United States), Acquired	Innovative medical device company focused on interventional solutions	$36.7M	Medtronic, Affinity Capital Management & 11 others	44/100
8th	Cerevast 2009, Bothell (United States), Series C	Medical device company developing innovative ultrasound and microsphere therapies	$46.9M	Swiftsure, Haiyin Capital	40/100
9th	Medical Instrument Development Laboratories 1981, San Leandro (United States), Acquired	Innovating ophthalmic surgical devices to prevent blindness and improve global vision	$50M	SBCVC, 6 Dimensions Capital & 3 others	38/100
10th	2C Tech Corporation 2010, Irvine (United States), Series B	Provider of nanotech-based medical devices to treat retinal disorders	$15.5M	Exsight Ventures, HOYA & 2 others	36/100
21st	Maculaser 2018, Espoo (Finland), Seed	Developer of laser therapy for the treatment of retinal diseases	$1.45M	Innovestor, Health Incubator Helsinki & 1 others	30/100